Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 1, 1989
[Prognosis in ovarian cancer as a function of the results of the second-look laparatomy]C Varette, A de Gramont, C Louvet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)A de Gramont, B Demuynck, C Varette, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 1, 1995
[Locoregional recurrences of breast cancer]J L Molitor, B Demuynck, C Louvet, et al.
British Journal of Cancer|April 20, 2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patientsM Mabro, P Artru, T André, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1997
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancerA de Gramont, J Vignoud, C Tournigand, et al.
La Revue De Medecine Interne|January 1, 1997
[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]A de Gramont, C Tournigand, C Louvet, et al.
Cancer|January 15, 1987
Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's diseaseA de Gramont, C Louvet, M Krulik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancerC Louvet, A de Gramont, B Demuynck, et al.
Cancer|August 1, 1986
Preleukemic changes in cases of nonlymphocytic leukemia secondary to cytotoxic therapy. Analysis of 105 casesA De Gramont, C Louvet, M Krulik, et al.
Bulletin Du Cancer|May 14, 2009
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II studyP Afchain, B Chibaudel, G Lledo, et al.
Pageof 13